EGFR and head and neck squamous cell carcinoma: Another targeted therapy, Cetuximab, an anti-epithelial growth factor receptor (EGFR) inhibitor, has been used for more than 10 years in R/M HNSCC as a monotherapy or in combination with platinum-based chemotherapeutic agents and taxanes [11,12,13].